14th World Congress on Advances in Alzheimers and Dementia
October 23-24, 2019 Melbourne, Australia
2nd International Conference on Bipolar Disorder: Depression and Psychiatry
November 11-12, 2019 Istanbul, Turkey
Movement disorders are neurological conditions that affect the speed, fluency, quality, and ease of movement. Abnormal fluency or speed of movement (called dyskinesia) may involve excessive or involuntary movement (hyperkinesia) or slowed or absent voluntary movement (hypokinesia). Electromyography (EMG) is a diagnostic procedure to assess the health of muscles and the nerve cells that control them (motor neurons).
The prevalence of all common categories of movement disorders was 28·0% (95% CI 25·9–30·1). Proportions in men (27·6% [95% CI 24·5–30·7]) and women (28·3% [25·5–31·2]) were closely similar and sharply increased with age (from 18·5% [15·0–22·0] in 50–59-year olds to 51·3% [44·9–57·7] in 80–89-year olds). Almost half of all patients (90/214) had moderate-to-severe disease expression, but only 7·0% (15/214) received standard drug treatment.
Caffeine and stress should be avoided, and good sleep is recommended.the first medication choices are beta blockers such as propranolol or alternately, nadolol and timolol. Atenolol and pindolol are not effective for tremor. The anti-epileptic primidone is also effective for movement disorders.Second-line medications are the anti-epileptics topiramate, gabapentin and levetiracetam, or benzodiazepines like alprazolam.